Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Status:
Completed
Trial end date:
2017-02-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma
of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.